Astria Therapeutics Signs an Exclusive License Agreement with Ichnos Sciences for OX40 Portfolio in Atopic Dermatitis and other Allergic and Immunological Diseases
Shots:
- Ichnos will receive a $15M upfront license fee, $20M in clinical development milestones for ~3 indications, and $285M on regulatory approval & commercial sales milestones for all licensed products along with royalties based on Astria’s and any of its affiliates or sublicensees’ annual net sales of the licensed products
- Astria will assume full cost & lead the global development and commercialization of the licensed therapeutic program for all indications. Astria plans to develop STAR-0310 (mAb OX40 antagonist) that incorporates YTE half-life extension technology for AD
- Astria is expected to submit an IND application at the end of 2024 with an expected initiation of a P-Ia trial in Q1’25 upon IND clearance while the P-Ib trial will initiate for AD & results expected in Q2’26
Ref: Businesswire | Image: Ichnos Sciences
Related News:- Ichnos Sciences’ ISB 2001 Receives the US FDA’s Orphan Drug Designation for the Treatment of Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
